Company intelligence / Profile preview

Leuko

Boston, Massachusetts, United Statesleuko.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Leuko is developing PointCheck™, a non-invasive optical device for at-home and point-of-care white blood cell monitoring. The technology aims to improve infection risk management for immunosuppressed patients by enabling frequent, painless testing without the need for blood draws. As of 2024–2025, the device is investigational and undergoing clinical validation; it is not yet commercially available. Early results suggest improved patient quality of life and potential healthcare cost savings.

Therapeutic areas: Hematology
Modalities: DeviceNon-pharmacological therapy
Industry: Physiological Monitoring

Partnerships

MIT/Madrid M+Vision ConsortiumGood Growth CapitalPegasus Tech VenturesNina Capital

Beyond the preview

Go deeper on Leuko.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leuko.

Explore the full profile